Continuing Cetuximab vs Bevacizumab plus chemotherapy after first progression in wild-type KRAS, NRAS and BRAF V600E metastatic colorectal cancer: a randomized phase II trial

To evaluate the clinical efficacy of continuing cetuximab vs bevacizumab plus chemotherapy crossover after first progression to cetuximab regimen in wild-type KRAS, NRAS and BRAF V600E mCRC, we conducted this prospective, open-label and randomized phase 2 trial in three cancer centers from Oct 1, 20...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:J Cancer
Main Authors: Li, Danyang, Wang, Feng, Xu, Shuning, Li, Ke, Meng, Xiangrui, Huang, Yangyang, Ma, Ning, Qiao, Lei, Kuang, Gaizhen, Chen, Jinghong, Liu, Ying
Format: Artigo
Sprog:Inglês
Udgivet: Ivyspring International Publisher 2021
Fag:
Research Paper
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8317523/
https://ncbi.nlm.nih.gov/pubmed/34335943
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/jca.60014
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker